基于腺病毒的前列腺癌治疗。

Maria Ekblad, Gunnel Halldén
{"title":"基于腺病毒的前列腺癌治疗。","authors":"Maria Ekblad,&nbsp;Gunnel Halldén","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is the second leading cause of cancer-related death in men in the Western world, despite efforts toward improving treatment strategies and earlier detection of this disease. A promising and relatively novel drug platform is virotherapy, which has demonstrated potent and selective antitumor efficacy in cancer cell lines and in preclinical in vivo tumor models, accompanied by minimal toxicity to normal cells. Safety and limited toxicity has also been demonstrated in many clinical trials targeting various solid cancers. Results from early-stage trials in patients with hormone-refractory prostate cancers have revealed potential efficacy following intraprostatic or intravenous delivery of replication-selective oncolytic viruses in combination with chemotherapeutics or radiation therapy. This review describes the most promising developments in virotherapy for prostate cancer, focusing on replication-selective adenoviral mutants as multimodal therapeutic agents.</p>","PeriodicalId":50605,"journal":{"name":"Current Opinion in Molecular Therapeutics","volume":"12 4","pages":"421-31"},"PeriodicalIF":0.0000,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adenovirus-based therapy for prostate cancer.\",\"authors\":\"Maria Ekblad,&nbsp;Gunnel Halldén\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prostate cancer is the second leading cause of cancer-related death in men in the Western world, despite efforts toward improving treatment strategies and earlier detection of this disease. A promising and relatively novel drug platform is virotherapy, which has demonstrated potent and selective antitumor efficacy in cancer cell lines and in preclinical in vivo tumor models, accompanied by minimal toxicity to normal cells. Safety and limited toxicity has also been demonstrated in many clinical trials targeting various solid cancers. Results from early-stage trials in patients with hormone-refractory prostate cancers have revealed potential efficacy following intraprostatic or intravenous delivery of replication-selective oncolytic viruses in combination with chemotherapeutics or radiation therapy. This review describes the most promising developments in virotherapy for prostate cancer, focusing on replication-selective adenoviral mutants as multimodal therapeutic agents.</p>\",\"PeriodicalId\":50605,\"journal\":{\"name\":\"Current Opinion in Molecular Therapeutics\",\"volume\":\"12 4\",\"pages\":\"421-31\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Molecular Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Molecular Therapeutics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在西方世界,前列腺癌是男性癌症相关死亡的第二大原因,尽管人们正在努力改进治疗策略和早期发现这种疾病。病毒治疗是一个很有前景的、相对较新的药物平台,它在癌细胞系和临床前体内肿瘤模型中显示出强大的、选择性的抗肿瘤功效,同时对正常细胞的毒性很小。在许多针对各种实体癌的临床试验中也证明了其安全性和有限毒性。激素难治性前列腺癌患者的早期试验结果显示,前列腺内或静脉注射复制选择性溶瘤病毒联合化疗或放疗的潜在疗效。本文综述了前列腺癌病毒治疗中最有前途的进展,重点介绍了复制选择性腺病毒突变体作为多模式治疗剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adenovirus-based therapy for prostate cancer.

Prostate cancer is the second leading cause of cancer-related death in men in the Western world, despite efforts toward improving treatment strategies and earlier detection of this disease. A promising and relatively novel drug platform is virotherapy, which has demonstrated potent and selective antitumor efficacy in cancer cell lines and in preclinical in vivo tumor models, accompanied by minimal toxicity to normal cells. Safety and limited toxicity has also been demonstrated in many clinical trials targeting various solid cancers. Results from early-stage trials in patients with hormone-refractory prostate cancers have revealed potential efficacy following intraprostatic or intravenous delivery of replication-selective oncolytic viruses in combination with chemotherapeutics or radiation therapy. This review describes the most promising developments in virotherapy for prostate cancer, focusing on replication-selective adenoviral mutants as multimodal therapeutic agents.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Opinion in Molecular Therapeutics
Current Opinion in Molecular Therapeutics 医学-生物工程与应用微生物
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信